Sandoz, Others Prevail In California Patent Dispute Over Biosimilar Treatment
SAN FRANCISCO — A California federal judge on Dec. 19 granted four defendants summary judgment of noninfringement with regard to a patent covering the neutropenia treatments Neupogen and Neulasta (Amgen Inc....To view the full article, register now.
Already a subscriber? Click here to view full article